Clinical Trials

Unlocking the Potential of Immunotherapy

  • Bladder Cancer Clinical Trials
  • Lung Cancer Clinical Trials
  • Head and Neck Cancer Clinical Trials
  • Pancreatic Cancer Clinical Trials
  • Other Clinical Trials
PHASE I
 
 
BISCAY—Durvalumab in CombinationAnti–PD-L1 + FGFR Inhibitor or PARP Inhibitor or WEE-1 Inhibitor or mTORC Inhibitor
Anti–PD-L1 + FGFR Inhibitor or PARP Inhibitor or WEE-1 Inhibitor or mTORC Inhibitor2L Muscle Invasive Bladder CancerNCT02546661

 
 
PHASE III
DANUBE—Durvalumab ± Tremelimumab
Anti–PD-L1 ± Anti–CTLA-41L BladderNCT02516241
PHASE I
 
 
Study 006—Durvalumab ± Tremelimumab
Anti–PD-L1 ± Anti–CTLA-4Advanced NSCLCNCT02000947

PHASE I
 
 
TATTON—Durvalumab + Osimertinib
Anti–PD-L1 + EGFR T790M TKIAdvanced NSCLCNCT02143466

PHASE I
 
 
Durvalumab + Gefitinib
Anti–PD-L1 + EGFR TKI2L+Locally Advanced or Metastatic NSCLCNCT02088112

 
PHASE II
 
Durvalumab Sequencing
Anti-PD-L1 following EGFR TKI or EGFR T790M or Anti-CTLA-4 or MEK Inhibitor + DocetaxelStage IIIB-IV NSCLCNCT02179671

 
PHASE II
 
ATLANTIC—Durvalumab
Anti–PD-L1Stage IIIB-IV NSCLCNCT02087423

 
 
PHASE III
POSEIDON
Anti–PD-L1 ± Anti–CTLA-4+Chemotherapy1L NSCLCNCT03164616

 
 
PHASE III
MYSTIC—Durvalumab ± Tremelimumab
Anti–PD-L1 ± Anti–CTLA-41L NSCLCNCT02453282

 
 
PHASE III
NEPTUNE—Durvalumab ± Tremelimumab
Anti–PD-L1 ± Anti–CTLA-41L NSCLCNCT02542293

 
 
PHASE III
PACIFIC—Durvalumab
Anti–PD-L1Unresectable Stage III NSCLCNCT02125461

 
 
PHASE III
ADJUVANT—Durvalumab
Anti–PD-L1Adjuvant Resected NSCLCNCT02273375

 
 
PHASE III
ARCTIC—Durvalumab ± Tremelimumab
Anti–PD-L1 ± Anti–CTLA-4Stage IIIB-IV NSCLCNCT02352948

 
 
PHASE III
Lung Master Protocol Durvalumab
Anti–PD-L1Stage IV Squamous NSCLCNCT02154490

 
 
PHASE III
CASPIAN—Durvalumab ± Tremelimumab
Anti–PD-L1 ± Anti–CTLA-41L SCLCNCT03043872

 
 
PHASE III
PEARL—Durvalumab vs SOC
Anti–PD-L11L NSCLCNCT03003962
PHASE I
 
 
Study 11—Durvalumab ± Tremelimumab
Anti–PD-L1 ± Anti–CTLA-42L Recurrent or Metastatic HNSCCNCT02262741

 
PHASE II
 
Durvalumab ± AZD9150 or AZD5069
Anti–PD-L1 ± STAT3 Inhibitor or CXCR2 Antagonist2L Recurrent or Metastatic HNSCCNCT02499328

 
 
PHASE III
KESTREL—Durvalumab ± Tremelimumab
Anti–PD-L1 ± Anti–CTLA-41L Recurrent or Metastatic HNSCCNCT02551159

 
 
PHASE III
EAGLE—Durvalumab ± Tremelimumab
Anti–PD-L1 ± Anti–CTLA-42L Recurrent or Metastatic HNSCCNCT02369874
 
PHASE II
 
Durvalumab + AZD5069
Anti–PD-L1 + CXCR2 AntagonistMetastatic Pancreatic Ductal CarcinomaNCT02583477
PHASE I
 
 
Durvalumab
Anti–PD-L1Solid TumorsNCT01938612

PHASE I
 
 
Study 10—Durvalumab + Tremelimumab
Anti–PD-L1 ± Anti–CTLA-4Advanced Solid TumorsNCT02261220

PHASE I
 
 
Durvalumab ± Tremelimumab
Anti–PD-L1 ± Anti–CTLA-4Advanced Solid TumorsNCT02141347

PHASE I
 
 
MEDI0562
OX40-AgonistAdvanced MalignanciesNCT02318394

PHASE I
 
 
Durvalumab
Anti–PD-L1Myelodysplastic SyndromeNCT02117219

PHASE I
 
 
Durvalumab + MEDI0680
Anti–PD-L1 + Anti–PD-1Advanced MalignanciesNCT02013804

PHASE I
 
 
Durvalumab + AZD6738
Anti–PD-L1 + ATR InhibitorSolid TumorsNCT02264678

PHASE I
 
 
Durvalumab or Tremelimumab + Mogamulizumab
Anti–PD-L1 or Anti–CTLA-4 + Anti–CCR4Solid TumorsNCT02301130

PHASE I
 
 
Durvalumab + MEDI9447
Anti–PD-L1 + CD73 InhibitorAdvanced MalignanciesNCT02503774

PHASE I
 
 
MEDI1873
GITR AgonistSolid TumorsNCT02583165

PHASE I
 
 
Durvalumab + Selumetinib
Anti–PD-L1 + MEK InhibitorAdvanced Solid TumorsNCT02586987

PHASE I
 
 
Durvalumab + AZD1775
Anti–PD-L1 + WEE-1 InhibitorAdvanced Solid TumorsNCT0261727

PHASE I
 
 
Durvalumab + Tremelimumab
Anti–PD-L1 ± Anti–CTLA-4Advanced Solid TumorsNCT02658214

PHASE I
 
 
Durvalumab + Monalizumab
Anti–PD-L1 + Anti-NKG2AAdvanced Solid TumorsNCT02671435

PHASE I
 
 
MEDI0562 + Durvalumab or Tremelimumab
OX40 Agonist + Anti–PD-L1 or Anti–CTLA-4Advanced MalignanciesNCT02705482

PHASE I
 
 
Durvalumab + AZD4635
Anti–PD-L1 + A2AR AntagonistAdvanced Solid TumorsNCT02740985

PHASE I
 
 
Durvalumab
Anti–PD-L1Solid TumorsNCT02900157

PHASE I
 
 
Durvalumab + MEDI9197
Anti–PD-L1 ± TLR7/8 AgonistAdvanced Solid MalignanciesNCT02556463

PHASE I
 
 
Durvalumab ± MEDI5083
Anti–PD-L1 ± Immune ActivatorAdvanced Solid TumorsNCT03089645

 
PHASE II
 
Durvalumab + Dabrafenib ± TrametinibAnti-PD-L1 + BRAF Inhibitor or MEK Inhibitor
Anti-PD-L1 + BRAF Inhibitor or MEK InhibitorMetastatic or Unresectable MelanomaNCT02027961

 
PHASE II
 
Study 21—Durvalumab ± Tremelimumab
Anti–PD-L1 ± Anti–CTLA-42L+ Gastric or GE JunctionNCT02340975

 
PHASE II
 
Study 1108—Durvalumab
Anti–PD-L1Solid TumorsNCT0169356

 
PHASE II
 
Tremelimumab
Anti–CTLA-4Various TumorsNCT02527434

 
PHASE II
 
STUDY 23—Durvalumab ± Tremelimumab ± AZD9150Anti–PD-L1 + Anti–CTLA-4 or STAT3 Inhibitor
Anti–PD-L1 + Anti–CTLA-4 or STAT3 InhibitorDiffuse Large B-cell LymphomaNCT02549651

 
PHASE II
 
MEDIOLA—Durvalumab + Olaparib Tablets
Anti–PD-L1 + PARP InhibitorVarious TumorsNCT02734004

 
PHASE II
 
STUDY 22—Durvalumab ± Tremelimumab
Anti–PD-L1 ± Anti–CTLA-4Hepatocellular CarcinomaNCT02519348

 
 
PHASE III
STRONG—Durvalumab ± Tremelimumab
Anti–PD-L1 ± Anti–CTLA-4Advanced Solid MalignanciesNCT03084471

PD-L1=programmed cell death ligand-1; FGFR=fibroblast growth factor receptor; PARP=poly ADP-ribose polymerase; mTORC=mammalian target of rapamycin complex; CTLA-4=cytotoxic T-lymphocyte–associated antigen 4; NSCLC=non-small cell lung cancer; EGFR=epidermal growth factor receptor; TKI=tyrosine kinase inhibitor; HNSCC=head and neck squamous cell carcinoma; STAT3=signal transducer and activator of transcription 3; GE=gastroesophageal; GITR=glucocorticoid-induced TNF receptor; A2AR=adenosine A2a receptor; TLR7/8=toll-like receptor 7/8.

References

1. Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res. 2013;19(5):997-1008. 2. AstraZeneca. Clinical trials appendix Q1 2017 results update. https://www.astrazeneca.com/content/dam/az/PDF/2017/QR1/Q1_2017_Results_Clinical_Trial_Appendix.pdf. Accessed May 10, 2017.